Navigation Links
New Research Reveals Mechanism By Which TNFerade(TM) Suppresses Metastases
Date:3/3/2010

GAITHERSBURG, Md., March 3 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) announced the publication of new preclinical research revealing mechanisms by which TNFerade(TM) suppresses cancer metastases through activation of the immune system.

This preclinical study, "Ad.Egr-TNF and Local Ionizing Radiation Suppress Metastases by Interferon-Beta-Dependent Activation of Antigen-specific CD8+ T Cells," authored by investigators from the University of Chicago and Harvard Medical School, appears in the recent issue of Molecular Therapy. The results illustrate that local treatment of an animal tumor with TNFerade suppresses metastases to lymph nodes by activating CD8+ T cells. Activation of these anti-tumor cells is mediated by Interferon-Beta, a known potent immune regulator.

"Although enhanced local control of cancer can contribute to improvements in patient survival, any suppression of metastases is an important aspect of cancer treatment. These exciting preclinical data may help explain the encouraging results being seen with TNFerade in the clinic," noted Mark Thornton, M.D., M.P.H., Ph.D., GenVec's Senior Vice President of Product Development.

About TNFerade(TM)

TNFerade is an adenovector, or DNA carrier, which contains the gene for tumor necrosis factor-alpha (TNF-alpha), an immune system protein with potent and well-documented anti-cancer effects, for direct injection into tumors. After administration, TNFerade stimulates the production of TNF-alpha in the tumor. GenVec is developing TNFerade for use in combination with radiation and/or chemotherapy for the treatment of various cancers.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. In addition, GenVec uses its proprietary adenovector technology to develop vaccines for infectious diseases including influenza, HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. GenVec also discovers and develops novel treatments for hearing loss and balance disorders through a worldwide collaboration with Novartis. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

    Investor Contact:
    GenVec, Inc.
    Danielle M. DiPirro
    (301) 944-1877
    ddipirro@genvec.com

    Media Contact:
    Tiberend Strategic Advisors, Inc.
    Andrew Mielach
    (212) 827-0020
    amielach@tiberendstrategicadvisors.com

SOURCE GenVec, Inc.

Back to top

RELATED LINKS
http://www.genvec.com

'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sorting device for analyzing biological reactions puts the power of a lab in a researchers pocket
2. U.S. Government Awards DuPont, Partners with Technology Investment Agreement for Macroalgae-to-Biobutanol Research
3. New Source for Science Funding: BenchFly Pioneers Search for Research Program
4. Stem Cell Innovations to Provide Research and Assay Services to Agennix.
5. Sunlight Research(TM), Releases its Osiris Therapeutics Stem Cell Patent Report
6. No New Findings in Atrazine Study Promoted by Discredited Researcher, According to the Hudson Institute Center for Global Food Issues
7. Funds Boost Research into Causes, Interventions for Age-Related Cognitive Decline
8. Stephen Coles is Recognized by Continental Whos Who Among Health Care Research Professionals
9. febits miRBase 14 Geniom-Biochip Now With 58 Additional New Sequences Available for Cancer Research
10. Researchers gain detailed insight into failing heart cells using new nano technique
11. Texas-Based Consortium Announces Project GreenVax: A Groundbreaking Vaccine Manufacturing Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... August 15, 2017 , ... Any expert in stem cell research or ... for more than half a century. Despite their essential roles in human health ... known that molecular tags developed for this purpose also tag other, more abundant, non-stem ...
(Date:8/15/2017)... (PRWEB) , ... August 15, 2017 , ... ... encrypted shopping cart. Now mobile responsive, the new website makes it easy to ... anywhere in between. Users can now find detailed product information, educational industry content ...
(Date:8/11/2017)... , Aug. 11, 2017  Market researcher ... York Times article regarding the telemedicine market.  ... to Kalorama Information.  The article, "Heart ... That"  used information from Kalorama Information,s ... & Telemedicine Market  (Sleep, Diabetes, Vital ...
(Date:8/10/2017)... Warsaw, Indiana (PRWEB) , ... August 09, 2017 ... ... is equipped to help the agriculture industry reach its ideal customers with the ... across the nation. , “As a Midwest company, we realize how crucial the ...
Breaking Biology Technology:
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... , April 11, 2017 No ... but researchers at the New York University Tandon ... of Engineering have found that partial similarities between ... systems used in mobile phones and other electronic ... The vulnerability lies in the fact ...
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
Breaking Biology News(10 mins):